Chongsheng Pharmaceuticals: The progress, evaluation, and approval results of innovative drug development projects all have uncertainties.

Zhongsheng Pharmaceutical announced a abnormal movement notice, indicating that the company is currently conducting two Phase III clinical trials for the treatment of children aged 2-11 with uncomplicated influenza A virus type and adolescents aged 12-17 with uncomplicated influenza A virus type using Angladavir granules and tablets, respectively. The company is also conducting a Phase III clinical trial for the treatment of obesity/overweight patients using RAY1225 injection, as well as two Phase III clinical trials for the treatment of type 2 diabetes patients using RAY1225 injection. The progress of innovative drug research and development projects, the results of evaluation and approval, as well as the future competitive landscape of the product market all have certain uncertainties. The approval and timing of market launch of drugs, as well as the production and sales situation after market launch, are uncertain. In addition, Angladavir tablets, a small molecule innovative drug for the treatment of uncomplicated influenza A in adults, has been approved for market by the National Medical Products Administration and is the world's first influenza RNA polymerase PB2 protein inhibitor. There are uncertainties regarding the commercialization and sales of Angladavir tablets in the future.